Pharmaceutical Industry

CNBC reports Eli Lilly and Novo Nordisk are both stepping up investment in amylin pathway drugs, viewed as the next-generation core mechanism after GLP-1 obesity therapies. New clinical data shows Lilly’s experimental combination therapy outperformed Zepbound on weight loss, signaling the obesity drug race has entered a new competitive cycle.

According to the Financial Times, British pharmaceutical giant AstraZeneca is in merger talks with US-based Bristol Myers Squibb. If completed, the deal would create one of the world’s largest pharmaceutical companies, sending shockwaves through the industry.